United Therapeutics Corporation

NasdaqGS:UTHR Stok Raporu

Piyasa değeri: US$16.7b

United Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

United Therapeutics şirketinin toplam hissedar öz sermayesi $6.1B ve toplam borcu $400.0M olup, bu da borç-öz sermaye oranını 6.6% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $7.1B ve $1.0B dir. United Therapeutics 'in FAVÖK'ü $1.3B faiz karşılama oranı -8.9 dur. Şirketin $3.3B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

6.6%

Borç/özkaynak oranı

US$400.00m

Borç

Faiz karşılama oranı-8.9x
NakitUS$3.33b
EşitlikUS$6.10b
Toplam yükümlülüklerUS$1.02b
Toplam varlıklarUS$7.12b

Son finansal sağlık güncellemeleri

Recent updates

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 18
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

Sep 27
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price

United Therapeutics: Economics Support Compounding Ability

Aug 20

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jul 26
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Jul 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

Jun 13
United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market

United Therapeutics: Exciting Company With A Big Problem

Jun 02

We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

Apr 05
We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease

United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects

Mar 20

Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Mar 15
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?

Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

Jan 02
Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Dec 08
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Nov 16
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Sep 04
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet

Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

Aug 07
Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today

United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

May 22
United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly

Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

Apr 25
Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?

We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

Feb 06
We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease

With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Jan 16
With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case

Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

Oct 20
Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?

United Therapeutics: Ability To Expand Tyvaso To Large IPF Market

Aug 24

Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

Aug 04
Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?

United Therapeutics Q2 2022 Earnings Preview

Aug 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: UTHR 'nin kısa vadeli varlıkları ( $4.0B ) kısa vadeli yükümlülüklerini ( $873.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: UTHR şirketinin kısa vadeli varlıkları ( $4.0B ) uzun vadeli yükümlülüklerini ( $148.8M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: UTHR şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: UTHR 'nin borç/öz sermaye oranı son 5 yılda 36.8% seviyesinden 6.6% seviyesine düştü.

Borç Kapsamı: UTHR 'nin borcu işletme nakit akışı ( 284.2% ) tarafından iyi bir şekilde karşılanmaktadır.

Faiz Kapsamı: UTHR ödediğinden daha fazla faiz kazandırıyor, dolayısıyla faiz ödemelerinin karşılanması bir sorun teşkil etmiyor.


Bilanço


Sağlıklı şirketleri keşfedin